Dr. Mudad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8333 NW 53rd street
first floor
Doral, FL 33166
Summary
- Facebook: Dr. Raja Mudad
Twitter: @DrMudad
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1992 - 1995- Duke University HospitalResidency, Internal Medicine, 1989 - 1992
American University of Beirut Faculty of MedicineClass of 1989
Certifications & Licensure
FL State Medical License 2006 - 2026
LA State Medical License 1995 - 2009- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Most Compassionate Doctor American Registry
Clinical Trials
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Start of enrollment: 2014 Sep 26
- Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Mar 23
- Join now to see all
Publications & Presentations
PubMed
- 25 citationsAssociation of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.Wungki Park, Laura Mezquita, Naoyuki Okabe, Young Kwang Chae, Deukwoo Kwon
British Journal of Cancer. 2020-02-04 - 45 citationsDeveloping a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With NivolumabWungki Park, Deukwoo Kwon, Diana Saravia, Amrita Desai, Fernando Vargas
Clinical Lung Cancer. 2017-12-01 - 21 citationsLongitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case seriesNishan Tchekmedyian, Raja Mudad, Fernando F. Blanco, Victoria M. Raymond, Jordan H. Garst
Lung Cancer. 2017-06-01
Press Mentions
Selective RET Inhibitors for RET Fusion-Positive Non-Small Cell Lung CancerMarch 27th, 2023- Sylvester Celebrates Doral Satellite OpeningSeptember 13th, 2022
Mesothelioma Clinical Trial Opens with Optimism in South FloridaApril 4th, 2018- Join now to see all
Professional Memberships
- Member
Other Languages
- Arabic, French, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
